Long-Term Endoscopic and Histological Outcomes of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis With up to 3 Years of Treatment

被引：0
|
作者：
Sands, Bruce E. [1 ]
Kobayashi, Taku [2 ]
Wu, Jianmin [3 ]
Wang, Isabella Yali [3 ]
Zhu, Baojin [3 ]
Redondo, Isabel [4 ]
Peyrin-Biroulet, Laurent [5 ,6 ]
Walsh, Alissa [7 ]
Magro, Fernando [8 ,9 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY USA
[2] Kitasato Univ, Kitasato Inst Hosp, Minato City, Tokyo, Japan
[3] Eli Lilly & Co, Indianapolis, IN USA
[4] Eli Lilly & Co, Lisbon, Portugal
[5] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vandoeuvre Les Nancy, France
[6] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[7] Oxford Univ Hosp, Translat Gastroenterol Unit, Oxford, England
[8] Univ Porto, Porto, Portugal
[9] Ctr Hosp, Porto, Portugal
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001035164.22459.94
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1449
引用
收藏
页码：S1042 / S1043
页数：2
相关论文
共 50 条
  • [1] Endoscopic and Histologic Remission After 2 Years Treatment With Mirikizumab in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Margo, Fernando
    Peyrin-Biroulet, Laurent
    Kobayashi, Taku
    Jairath, Vipul
    Walsh, Alissa
    Christensen, Britt
    Wu, Jianmin
    Park, Gina
    Redondo, Isabel
    Sands, Bruce E.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S812 - S812
  • [2] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Doug
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2012, 18 : S20 - S21
  • [3] Long-Term Efficacy of Adalimumab for Treatment of Moderately to Severely Active Ulcerative Colitis
    Colombel, Jean-Frederic
    Sandborn, William
    Wolf, Douglas
    Panaccione, Remo
    Lazar, Andreas
    Kron, Martina
    Robinson, Anne
    Thakkar, Roopal
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S652 - S652
  • [4] Long-term use of ozanimod in patients with moderately to severely active Ulcerative Colitis
    Danese, S.
    Colombel, J. F.
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A.
    Chitkara, D.
    Marta, C.
    Charles, L.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V.
    Wolf, D. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I093 - I094
  • [5] LONG-TERM USE OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Wolf, Douglas C.
    Colombel, Jean Frederic
    Ponich, Terry P.
    Jovanovic, Igor
    Bossuyt, Peter
    Longman, Randy
    Alekseeva, Olga
    Petersen, AnnKatrin
    Chitkara, Denesh
    Marta, Cecilia
    Charles, Lorna
    Rubin, David T.
    Afzali, Anita
    Loftus, Edward V.
    Danese, Silvio
    GASTROENTEROLOGY, 2022, 162 (07) : S969 - S969
  • [6] Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
    Danese, S.
    Colombel, J-F
    Ponich, T.
    Jovanovic, I.
    Bossuyt, P.
    Longman, R.
    Alekseeva, O.
    Petersen, A. K.
    Marta, C.
    Charles, L.
    Sparrow, M.
    Rubin, D. T.
    Afzali, A.
    Loftus, E. V., Jr.
    Wolf, D. C.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 125 - 126
  • [7] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    INFLAMMATORY BOWEL DISEASES, 2020, 26 : S10 - S11
  • [8] MIRIKIZUMAB TREATMENT IMPROVES BOWEL MOVEMENT URGENCY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla
    Lee, Scott D.
    Panaccione, Remo
    Abreu, Maria
    Vermeire, Severine
    Lissoos, Trevor
    Morris, Nathan
    Arora, Vipin
    Dong, Yan
    Naegeli, April
    Sands, Bruce
    GASTROENTEROLOGY, 2020, 158 (03) : S17 - S18
  • [9] EFFECT OF MIRIKIZUMAB ON CLINICAL AND ENDOSCOPIC OUTCOMES BASED ON PRIOR ADVANCED THERAPY FAILURE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Navabi, Seyedehsan
    D'Haens, Geert
    Samaan, Karen H.
    Li, Xingyuan
    Arora, Vipin
    Redondo, Isabel
    Danese, Silvio
    GASTROENTEROLOGY, 2023, 164 (06) : S1089 - S1089
  • [10] Effect of mirikizumab on clinical and endoscopic outcomes based on prior advanced therapy failure in patients with moderately to severely active ulcerative colitis
    Navabi, S.
    D'Haens, G.
    Samaan, K. H.
    Li, X.
    Arora, V.
    Redondo, I.
    Danese, S.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 598 - 598
12345